About Solexa
Solexa is a company based in Hayward (United States) founded in 1992 was acquired by Illumina in November 2006. Solexa has raised $14.4 million across 5 funding rounds from investors including Illumina, Abingworth and ValueAct Capital. Solexa has completed 1 acquisition, including Lynx Therapeutics. Solexa operates in a competitive market with competitors including StrideBio, LogicBio, Phase Genomics, Candel Therapeutics and Rejuvenate Bio, among others.
- Headquarter Hayward, United States
- SectorsHealthcare
- Phone•••• ••••
- Website solexa.com
- Acquired by Illumina (Nov 2006)
Funding Insights of Solexa
Solexa has successfully raised a total of $14.4M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in December 2006. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.4M
- Total Rounds 5
- Last Round Post-IPO — $50M
- First Round $1.3M
(Mar 2004)
- Investors Count 5
All 5 funding rounds of Solexa with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2006 | $50M | Post-IPO | – | – | – |
| Feb 2006 | $65M | Post-IPO | – | – | – |
| Apr 2005 | $32.5M | Post-IPO | – | – | |
| Sep 2004 | $14.4M | Series B | – | Amadeus Capital | |
| Mar 2004 | $1.3M | Grant | – | – | – |
6 investors in total: 6 institutional.
Investors in Solexa
Solexa has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Illumina, Abingworth and ValueAct Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investment firm based out of USA | – | valueact.com | San Francisco, United States | |
Early-stage deep technology investments are made by Amadeus Capital. | – | amadeuscapital.com | London, United Kingdom | |
Early stage VC firm investing in the US and Korea | – | oxbio.com | Boston, United States | |
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Venture capital fund focused on early-stage healthcare startups | – | svhealthinvestors.com | Boston, United States | |
Developer of technologies for analysis of genetic variation and function | 1993 | illumina.com | San Diego, United States |
Investor details for Solexa
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Solexa
1 people are tracked at Solexa (1 in leadership).
| Name | Role | Group |
|---|---|---|
Francis deSouza | CEO | Leadership |
Complete people profiles for Solexa
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Solexa
Solexa has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Lynx Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Molecular sequence diagnostics are developed for life science sectors. | lynxgen.com | Hayward, United States | 1992 | Sep 2004 | $56M |
Complete acquisition details for Solexa
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Solexa
5 dated milestones of Solexa across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Solexa is founded.
- Funding First funding round of $1.3M.
- Acquisition Acquires Lynx Therapeutics.
- Exit Acquired by Illumina.
- Funding Latest funding round, Post-IPO, of $50.0M.
Competitors of Solexa
Solexa operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as StrideBio, LogicBio, Phase Genomics, Candel Therapeutics and Rejuvenate Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. | |
| logicbio.com | 2013 | Lexington, United States | $49M | 62 | Viral vectors are developed for genetic and infectious disease treatments. | |
| phasegenomics.com | 2015 | Seattle, United States | $5.75M | 19 | Laboratory and computational services for DNA proximity analysis are provided. | |
| candeltx.com | 1999 | United States | $110.3M | 76 | Viral immunotherapies are developed for cancer treatment. | |
| rejuvenatebio.com | 2017 | San Diego, United States | $14.58M | 39 | Gene-editing platform and anti-aging therapy for dogs are developed. | |
| novogene.com | 2011 | Beijing, China | $75M | 141 | Genomic services and solutions with NGS expertise are provided. | |
| sixfold.bio | 2017 | London, United Kingdom | $4.59M | 16 | Oligonucleotide delivery systems are developed for targeted gene therapy. | |
| genedit.com | 2016 | Berkeley, United States | $93.5M | 34 | Genetic medicines are delivered using polymer nanoparticle platforms. | |
| clinical-microbiomics.com | 2016 | Horsholm, Denmark | $9.71M | 35 | Meta-genomics platforms and services for microbiome studies are provided. | |
| bgi.com | 1999 | Shenzhen, China | – | 25 | BGI is engaged in genomics and precision medicine solutions. |
Detailed competitors of Solexa
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Solexa
Complete news archive for Solexa
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Solexa
10 companies that operate in the same segment as Solexa (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Solexa
Solexa was founded in 1992 and raised its 1st funding round 12 years after it was founded.
Solexa is headquartered in Hayward, United States. It is registered at Hayward, California, United States.
Francis deSouza is the current CEO of Solexa.
Solexa is a funded company, having raised a total of $14.4M across 5 funding rounds to date. The company's 1st funding round was a Grant of $1.3M, raised on Mar 2004.
Solexa is a spin-off from the University of Cambridge. The founders of this company were the first to develop sequencing by synthesis technology (the basis for most of the next generation sequencing technologies). In 2001 the company acquired Manteias molecular clustering technology to amplify the DNA molecules in cluster increasing the efficiency further. In the year 2005 the company successfully sequenced the complete genome of bacteriophage phiX-174 and went public the same year. It was acquired by Illumina in 2007.
Solexa's top competitors include Novogene Corporation, Phase Genomics and BGI.
Solexa has made 1 acquisition, including Lynx Therapeutics.
Solexa has 6 investors. Key investors include Illumina, Abingworth, ValueAct Capital, Amadeus Capital Partners, and Oxford Bioscience Partners.
Yes. Solexa was acquired by Illumina in November 2006.